About BBOT Dividend Returns
BridgeBio Oncology Therapeutics Inc. (BBOT) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.
How We Calculate Total Return
Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.
Frequently Asked Questions
Q1What is the total return of BBOT over the past year?
BridgeBio Oncology Therapeutics Inc. (BBOT) delivered a return of -9.23% over the past year. Since BBOT does not currently pay dividends, the total return equals the price-only return.
Q2How much would $10,000 invested in BBOT be worth today?
A $10,000 investment in BridgeBio Oncology Therapeutics Inc. one year ago would be worth $9,077 today, representing a loss of $923.
Q3Does BBOT pay dividends?
BridgeBio Oncology Therapeutics Inc. (BBOT) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For BBOT, the total return equals the price-only return.
Q4Did BBOT beat the S&P 500?
No, BridgeBio Oncology Therapeutics Inc. (BBOT) underperformed the S&P 500 by 24.68 percentage points over the past year. BBOT delivered a total return of -9.23%, compared to the S&P 500's 15.45%. This means a passive S&P 500 index fund outperformed BBOT by 24.68pp during this period.
Q5What is BBOT's worst drawdown?
BridgeBio Oncology Therapeutics Inc. (BBOT) experienced a maximum drawdown of -27.31% over the past year, declining from its peak on 2025-11-17 to its trough on 2026-02-20. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.
Q6What is BBOT's long-term total return over 10, 20, or 30 years?
BridgeBio Oncology Therapeutics Inc. (BBOT) has delivered strong long-term returns with dividends reinvested. Over 10 years, the total return is -1.6% (-0.2% CAGR) — $10,000 would have grown to $9,843. Over 20 years: -1.6% total return (-0.1% CAGR) — $10,000 → $9,843. Over 30 years: -1.6% total return (-0.1% CAGR) — $10,000 → $9,843. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.
Q7What was BBOT's best and worst year?
BridgeBio Oncology Therapeutics Inc.'s best calendar year was 2025 with a total return of 13.9%. Its worst year was 2024 with a total return of 3.0%. This range shows the volatility investors should expect — the difference between the best and worst year is 10.9 percentage points.
Find the Best Dividend Stocks
Screen for dividend stocks with the highest total returns (including DRIP).